Edition:
United States

PTC Therapeutics Inc (PTCT.OQ)

PTCT.OQ on NASDAQ Stock Exchange Global Select Market

34.88USD
3:59pm EST
Change (% chg)

$0.21 (+0.61%)
Prev Close
$34.67
Open
$35.02
Day's High
$35.68
Day's Low
$33.97
Volume
252,371
Avg. Vol
297,429
52-wk High
$52.95
52-wk Low
$15.60

Chart for

About

PTC Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered... (more)

Overall

Beta: 2.36
Market Cap(Mil.): $1,709.91
Shares Outstanding(Mil.): 50.45
Dividend: --
Yield (%): --

Financials

  PTCT.OQ Industry Sector
P/E (TTM): -- 95.96 30.88
EPS (TTM): -1.70 -- --
ROI: -12.98 0.60 13.80
ROE: -29.51 -2.18 15.29

BUZZ-PTC Therapeutics: Jumps on deal to buy Agilis Biotherapeutics

** Drug developer's shares up nearly 9 pct at $40.07 in early trading on Friday

Jul 20 2018

Roche SMA drug shines in study as costly new therapies advance

ZURICH A drug being co-developed by Roche to treat spinal muscular atrophy (SMA) helped improve development scores in babies with the genetic disease, a study released on Monday showed, as the race heats up for therapies destined to be among the drug industry's most expensive.

Jun 18 2018

Roche SMA drug shines in study as costly new therapies advance

ZURICH, June 18 A drug being co-developed by Roche to treat spinal muscular atrophy (SMA) helped improve development scores in babies with the genetic disease, a study released on Monday showed, as the race heats up for therapies destined to be among the drug industry's most expensive.

Jun 18 2018

Earnings vs. Estimates